(image: AGC Biologics)
Chiba, April 8 (Korea Bizwire) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced the appointment of Jun Takami as the General Manager/Site Head, to lead the continued successful operations as well as continuous improvements at its Chiba, Japan site.
Mr. Takami’s transition to the Site Head comes after a tremendously successful tenure as the Project Manager Director at the Japan facility – a role he assumed in 2017 when joining AGC Biologics.
“We are incredibly pleased that Mr. Takami has accepted the promotion to become the General Manager/Site Head for the Chiba site. He brings rich technical experience from our industry, and deep experience across many of our core business functions,” said AGC Biologics Chief Technical Officer, Kasper Møller. “I’m fully confident that Mr. Takami will ensure successful delivery of all of our customer programs at our Chiba facility and further expand the site operations to meet future demands.”
Mr. Takami brings over 15 years of experience in the pharmaceutical industry, with roles in process development, GMP manufacturing, process engineering and PLI activities with the Roche group at Chugai Pharmaceuticals. He holds a Master of Biological Science from Kobe University.
About AGC Biologics:
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to deliver the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells. Our global network spans the U.S., Europe and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 1,600 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.
David Self
AGC Biologics
dself@agcbio.com
Source: AGC Biologics via GLOBE NEWSWIRE
